GlycoVaxyn and Glaxosmithkline | Date: 2014-10-13
Described herein are modified host cells useful in the production of bioconjugates that can be used to vaccinate subjects against infection with Pseudomonas. The genomes of the modified host cells described herein comprise genes that encode proteins involved in glyosylation of proteins as well as genes specific to the production of Pseudomonas-specific antigens.
GlycoVaxyn | Date: 2013-11-07
Prokaryotic cells proficient to produce glycoconjugates in vivo are provided herein, as well as methods for generating these cell and methods of using these cells to produce glycoconjugates. The compositions of the mentioned glycoconjugates as well as their different uses are also included.
GlycoVaxyn | Date: 2015-02-23
Provided herein is a novel E. coli O polysaccharide, O25B. Also provided herein are prokaryotic host cells comprising enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates comprise O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, comprising O25B and/or bioconjugates comprising O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further comprise one or more additional bioconjugates.
GlycoVaxyn | Date: 2013-09-10
Provided herein is a bioconjugate comprising a carrier protein and a modified antigen of Escherichia coli, the O antigen 0121. Also provided herein are uses of said bioconjugate, such as the treatment and/or prevention of diseases caused by Salmonella enterica, including diseases caused by Salmonella enterica subspecies I serovar Typhi (S. typhi).
GlycoVaxyn | Date: 2013-10-11
Described herein are novel methods of inserting nucleic acid sequences into host cells. Also described herein are genetically stable host cells comprising inserted nucleic acid sequences and methods of using such host cells in the generation of proteins.
GlycoVaxyn | Date: 2014-09-23
The present invention encompasses a novel S. aureus bioconjugate vaccine. More generally, the invention is directed to Gram-positive and other bioconjugate vaccines containing a protein carrier, at least one polysaccharide such as a capsular Gram-positive polysaccharide, and, optionally, an adjuvant or pharmaceutically acceptable carrier. The instant invention also includes methods of producing Gram-positive and other bioconjugate vaccines. An N-glycosylated protein is also provided that contains one or more polysaccharides such as Gram-positive polysaccharides. The invention is additionally directed to engineered prokaryotic organisms comprising nucleotide sequences encoding a glycosyltransferase of a first prokaryotic organism and a glycosyltransferase of a second prokaryotic organism. The invention further includes plasmids and prokaryotic cells transformed with plasmids encoding polysaccharides and enzymes which produce an N-glycosylated protein and/or bioconjugate vaccine. Further, the invention is directed to methods of inducing an immune response in a mammal comprising administering said bioconjugate vaccines.
GlycoVaxyn | Date: 2014-12-03
Provided herein are immunogenic compositions and vaccines for the treatment and prevention of Staphylococcus aureus infections. These immunogenic compositions and vaccines comprise combinations of bioconjugates capsular polysaccharides that are N-linked to one or more carrier proteins.
GlycoVaxyn | Date: 2012-09-06
Provided herein are prokaryotic cells capable of producing bioconjugates comprising glycosylated proteins. Also provided herein are compositions comprising such bioconjugates and/or comprising the saccharide moieties of such bioconjugates, as well as methods of vaccinating subjects using such compositions.
GlycoVaxyn | Date: 2014-08-18
The invention is directed to bioconjugate vaccines comprising N-glycosylated proteins. Further, the present invention is directed to a recombinant prokaryotic biosynthetic system comprising nucleic acids encoding an epimerase that synthesizes an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus. The invention is further directed to N-glycosylated proteins containing an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus and an expression system and methods for producing such N-glycosylated proteins.
GlycoVaxyn | Date: 2014-10-23
The present invention is directed to a bioconjugate vaccine, such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.